Efficacy and Safety of Zanubrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

NCT03206918 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

91

Enrollment

INDUSTRY

Sponsor class

Conditions

Relapsed or Refractory Chronic Lymphocytic Leukemia
Relapsed or Refractory Small Lymphocytic Lymphoma

Interventions

DRUG: Zanubrutinib

Sponsor

BeiGene